<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl16" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size d</th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>CD34<sup>+</sup>/CD31<sup>&#8722;</sup></td><td>CD45<sup>+</sup></td><td>3.974546</td><td>94.6%<xref ref-type="table-fn" rid="tblfn5">*</xref></td><td>3<xref ref-type="table-fn" rid="tblfn5">*</xref></td><td>3<xref ref-type="table-fn" rid="tblfn5">*</xref></td></tr><tr><td>CD31<sup>+</sup></td><td>CD45<sup>+</sup></td><td>1.838290</td><td>81.8%</td><td>6</td><td>6</td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><label>*</label><p>6 tumors will be used per group based on the CD31<sup>+</sup> to CD45<sup>+</sup> comparison making the power 99.9%.</p></fn></table-wrap-foot></table-wrap>